NCT00182702View on ClinicalTrials.gov

Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2007

Conditions
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Interventions
DRUG

ixabepilone

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00182702 - Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | Biotech Hunter | Biotech Hunter